Questcor buys Synacthen from Novartis in Acthar defensive move

Questcor Pharmaceuticals's stock closed 14.7% higher on 11 June after the company announced that it will double the number of commercial assets in its portfolio – and protect its only US FDA-approved product from competition – with the acquisition of Synacthen and Synacthen Depot from Novartis for $60 million plus at least $75 million in future payments.